Immatics N.V. — Investor Relations & Filings

Immatics N.V. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for cancer. The company's approach combines the discovery of novel cancer targets with the development of corresponding T cell receptors (TCRs) to treat solid tumors. It operates through two primary therapeutic modalities: Adoptive Cell Therapies (ACT), which involve engineering a patient's T cells, and TCR Bispecifics, which are off-the-shelf biologics. Immatics is a leader in the precision targeting of PRAME, a protein expressed in over 50 different types of cancer. Its clinical pipeline includes multiple product candidates targeting PRAME, aiming to address significant unmet medical needs for a broad patient population.